Your browser doesn't support javascript.
loading
A Multicenter, Retrospective Outcome Analysis of Vancomycin Area Under the Curve versus Trough-Based Dosing Strategies in Patients with Burn OR Inhalational Injuries (MONITOR).
Santos, Richard; Boyd, Allison N; Walroth, Todd A; Hall, Alexandria; King, Jessie; Ahiskali, Aileen; Walter, Ellen; Neumann, Nichole; Curry, Dominick; Hoyte, Brittany; Thomas, Wendy; Adams, Beatrice; Tran, Nicolas; Gleason, Vanessa M; Drabick, Zachary; DeWitt, Alexandra; Suarez, Justin; Prazak, Ann Marie B; Disney, Kathryn A; Hill, David.
  • Santos R; Department of Pharmacy, Regional One Health, 877 Jefferson Avenue, Memphis, TN 38103, USA.
  • Boyd AN; Department of Pharmacy, Eskenazi Health, 720 Eskenazi Avenue, Indianapolis, IN 46202, USA.
  • Walroth TA; Department of Pharmacy, Eskenazi Health, 720 Eskenazi Avenue, Indianapolis, IN 46202, USA.
  • Hall A; Department of Pharmacy, Harborview Medical Center, 325 9th Avenue, Seattle, WA 98104, USA.
  • King J; Department of Pharmacy, Harborview Medical Center, 325 9th Avenue, Seattle, WA 98104, USA.
  • Ahiskali A; Department of Pharmacy, Hennepin Healthcare, 701 Park Avenue, Minneapolis, MN 55415, USA.
  • Walter E; Department of Pharmacy, Hennepin Healthcare, 701 Park Avenue, Minneapolis, MN 55415, USA.
  • Neumann N; Department of Pharmacy, Hennepin Healthcare, 701 Park Avenue, Minneapolis, MN 55415, USA.
  • Curry D; Department of Pharmacy Services, Orlando Health, 1414 Kuhl Avenue, Orlando, FL 32806, USA.
  • Hoyte B; Department of Pharmacy, Corewell Health West, 100 Michigan St. NE, Grand Rapids, MI, 49503, USA.
  • Thomas W; Department of Pharmacy, Corewell Health West, 100 Michigan St. NE, Grand Rapids, MI, 49503, USA.
  • Adams B; Department of Pharmacy, Tampa General Hospital, 1 Tampa General Circle, Tampa, FL 33606, USA.
  • Tran N; Department of Pharmacy, Tampa General Hospital, 1 Tampa General Circle, Tampa, FL 33606, USA.
  • Gleason VM; Department of Pharmacy, Thomas Jefferson University Hospital, 111 South 11th Street, Philadelphia, PA 19107, USA.
  • Drabick Z; Department of Pharmacy, University of Florida Health Shands Hospital, 1600 SW Archer Rd, Gainesville, FL 32608, USA.
  • DeWitt A; Department of Pharmacy, University Medical Center New Orleans, 2000 Canal Street, New Orleans, LA 70112, USA.
  • Suarez J; Clinical Pharmacist, Department of Pharmaceutical Care, University of Iowa Health Care Medical Center, 200 Hawkins Drive, Iowa City, IA 52242, USA.
  • Prazak AMB; Department of Pharmacy Services, University of Utah Health, 50 N Medical Drive, Salt Lake City, UT 84132, USA.
  • Disney KA; Department of Pharmacy Services, University of Utah Health, 50 N Medical Drive, Salt Lake City, UT 84132, USA.
  • Hill D; Department of Pharmacy, Regional One Health, 877 Jefferson Avenue, Memphis, TN 38103, USA.
J Burn Care Res ; 2024 Jun 20.
Article en En | MEDLINE | ID: mdl-38900835
ABSTRACT
Vancomycin is a glycopeptide antibiotic that requires close therapeutic monitoring. Prolonged exposure to elevated concentrations increases risk for serious adverse effects such as nephrotoxicity. However, sub-therapeutic concentrations may lead to bacterial resistance and clinical failure or death. The most recent Infectious Diseases Society of America (IDSA) publication regarding therapeutic monitoring of vancomycin recommends utilizing area under the curve (AUC)-based monitoring to maximize clinical success. Despite the guideline recommendation for AUC-guided dosing, many institutions still use trough-only monitoring in their practices, including those caring for patients with acute burn injuries. Following burn injury, patients are at a higher risk for infections, multi-organ failure, and pharmacokinetic alterations. The primary objective of this multi-center retrospective study is to determine optimal therapeutic monitoring of vancomycin by comparing clinical success between AUC vs. trough-based monitoring in burn patients. MONITOR was a multicenter, retrospective study of patients with thermal or inhalation injury admitted to one of 13 burn centers from 1/1/17 to 8/31/22 who received vancomycin. Demographic and clinical course data, including acute kidney injury (AKI) incidence and clinical success were obtained. Patients were evaluated for clinical success and grouped according to method of monitoring and adjusting doses AUC vs. trough-based monitoring. Clinical success was a composite definition and lack of meeting any 1 of 5 criteria 1) persistent infection, 2) relapse, 3) antibiotic failure (clinical worsening), 4) AKI, 5) death. Five-hundred seventeen vancomycin courses were assessed from 485 patients. There was no difference in the rate of clinical success between AUC monitored and the trough-only monitored groups. Incidence of AKI was higher in the trough-only group; however, was not statistically significant after controlling for renal function on admission, past medical history of chronic kidney disease (CKD), and concomitant nephrotoxins.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article